Amgen Inc.
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Robert A. Bradway
- Full Time Employees
- 28,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- One Amgen Center Drive Thousand Oaks CA United States of America 91320-1799
- IPO Date
- Jun 17, 1983
- CIK
- 0000318154
- Website
- amgen.com
- Similar Companies
- Business
- Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Company News
Amgen: Biosimilars And Rare Disease Pipeline Crucial To Overcome Patent Cliff Concerns
What Makes Amgen (AMGN) a New Buy Stock
Are Medical Stocks Lagging Amgen (AMGN) This Year?
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
Amgen: Great Starting Yield For This Wealth Compounder
Amgen (AMGN) is a Top-Ranked Growth Stock: Should You Buy?
Amgen (AMGN) Falls More Steeply Than Broader Market: What Investors Need to Know
1 Top Dividend Growth Stock to Buy Right Now
Amgen: A Defensive Biotech With Yield And Optionality
Amgen (AMGN) Advances While Market Declines: Some Information for Investors
Amgen (AMGN) Outperforms Broader Market: What You Need to Know
Final Trades: Amgen, Caterpillar, Honeywell and Freeport-McMoran
This GLP-1 Stock's Bad News Could Be a Big Win for Eli Lilly and Novo Nordisk
Trading Rotation Kicks Off 2nd Half of 2025
Why Amgen Stock Popped by 4% Today
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Amgen's gastric cancer drug meets late-stage trial goal
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
2 Dividend Stocks to Buy on the Dip and Hold Forever
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?